SKB264
merck,daiichi sankyo,astrazeneca,gilead,klus
['$gild', '$dsnky', '$azn', '$mrk']
one year on, $mrk's savvy kelun deal might be delivering. take on trop2, perhaps an underappreciated mechanism at #asco23 -&gt; $gild $azn $dsnky
Once had a blue tick. Journalist at Evaluate Vantage. Interested in: oncology, immunology. Not interested in: what stock you bought today.